Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash of $18.48M in Q2 FY2026
Q2 FY2026 net change in cash was $18.48M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (14.15M) USD
- Year-over-year change
- —
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.15M) | — |
Net Change in Cash vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 net change in cash of $14.15M is the 9th largest of the 10 companies compared; the peer median is $9.2M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $138.36M | -203.9% | — | 1942.9% | |
| LTM Jun 2026 | $91.87M | +1015.5% | +138.5% | — | |
| LTM Mar 2026 | $67.03M | +416.2% | — | 181.9% | |
| LTM Mar 2026 | $61.31M | -209.6% | -38.7% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $61.23M | -167.8% | +31.0% | — |
| LTM Mar 2026 | $48.5M | +262.3% | — | 134713.9% | |
| LTM Mar 2026 | $21.06M | +126.4% | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $15.71M | -119.6% | +70.2% | 152.3% |
KLRAKailera Therapeutics, Inc. | FY2025 | $14.15M | — | — | — |
| LTM Mar 2026 | $9.2M | +108.4% | -58.2% | — | |
| Peer median (excluding KLRA) | $9.2M | +108.4% | +31.0% | 1062.4% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (148.96M) |
| Depreciation & Amortization | 310K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 10.94M |
| Change in Working Capital | 16.78M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 4.69M |
| Other Working Capital | 12.09M |
| Other Non-Cash Items | 714K |
| Operating Cash Flow | (120.21M) |
| Capital Expenditures | (2.09M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (632.16M) |
| Sales of Investments | 141.65M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (492.6M) |
| Debt Repayment | 100M |
| Common Stock Issued | 498.97M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (499.19M) |
| Financing Cash Flow | 598.66M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | (14.15M) |
| Free Cash Flow | (122.3M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.